NCT04256707 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 23
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 79
- units
- Participants
- groups
- description
- Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally on Day 1 followed by Tablet B (selinexor 1 × 100 mg tablet) orally on Day 8 (S20-100) until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG000
- title
- Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)
- description
- Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally on Day 1 followed by Tablet A (selinexor 5 × 20 mg tablets) orally on Day 8 (S100-20) until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG001
- title
- Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)
- description
- Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG002
- title
- Monotherapy: Moderate Hepatic Function (Tablet A Only)
- description
- Participants with severe hepatic function received Tablet A (selinexor 2X20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG003
- title
- Monotherapy: Severe Hepatic Function (Tablet A Only)
- description
- Participants with non-small cell lung cancer received selinexor 60 mg orally QW and docetaxel 75 mg/m\^2 IV once for every 3 weeks until PD or intolerable toxicity up to 25 months.
- id
- BG004
- title
- Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel
- description
- Participants with colorectal cancer received selinexor 80 mg orally QW and pembrolizumab 200 mg IV once every 3 weeks until PD or intolerable toxicity up to 25 months.
- id
- BG005
- title
- Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab
- description
- Participants with colorectal cancer received selinexor 40 mg orally on Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5- fluorouracil (5-FU) 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.
- id
- BG006
- title
- Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)
- description
- Participants with colorectal cancer received selinexor 80 mg orally on Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5-FU 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.
- id
- BG007
- title
- Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 19
- title
- 18 - 50
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 32
- title
- 51 - 64
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 20
- title
- 65 - 74
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 8
- title
- ≥75
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 23
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 79
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 78
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Baseline characteristics were summarized for all unique enrolled participants who received monotherapy and combination therapy.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 23
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 79
- units
- Participants
- groups
- description
- Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally on Day 1 followed by Tablet B (selinexor 1 × 100 mg tablet) orally on Day 8 (S20-100) until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG000
- title
- Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B)
- description
- Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally on Day 1 followed by Tablet A (selinexor 5 × 20 mg tablets) orally on Day 8 (S100-20) until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG001
- title
- Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A)
- description
- Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG002
- title
- Monotherapy: Moderate Hepatic Function (Tablet A Only)
- description
- Participants with severe hepatic function received Tablet A (selinexor 2X20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision up to 4 months.
- id
- BG003
- title
- Monotherapy: Severe Hepatic Function (Tablet A Only)
- description
- Participants with non-small cell lung cancer received selinexor 60 mg orally QW and docetaxel 75 mg/m\^2 IV once for every 3 weeks until PD or intolerable toxicity up to 25 months.
- id
- BG004
- title
- Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel
- description
- Participants with colorectal cancer received selinexor 80 mg orally QW and pembrolizumab 200 mg IV once every 3 weeks until PD or intolerable toxicity up to 25 months.
- id
- BG005
- title
- Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab
- description
- Participants with colorectal cancer received selinexor 40 mg orally on Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5- fluorouracil (5-FU) 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.
- id
- BG006
- title
- Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)
- description
- Participants with colorectal cancer received selinexor 80 mg orally on Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5-FU 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.
- id
- BG007
- title
- Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 19
- title
- 18 - 50
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 32
- title
- 51 - 64
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 20
- title
- 65 - 74
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 8
- title
- ≥75
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 23
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 79
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 78
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Baseline characteristics were summarized for all unique enrolled participants who received monotherapy and combination therapy.
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice
Triangle